# New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)

> **NCT01482104** · NA · COMPLETED · sponsor: **Norwegian University of Science and Technology** · enrollment: 277 (actual)

## Conditions studied

- Skin Neoplasms
- Carcinoma, Basal Cell

## Interventions

- **DRUG:** MAL-PDT re-treatment
- **DRUG:** usual MAL-PDT

## Key facts

- **NCT ID:** NCT01482104
- **Lead sponsor:** Norwegian University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2017-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482104, "New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01482104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*